Insmed, Inc.
INSM
$117.99
+1.72%
Insmed, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, operating primarily within the biotechnology sector. The company has established a commercial presence with its two approved respiratory products, Arikayce and Brinsupri, and is building a pipeline across immunology, inflammation, and neuro/rare diseases, positioning it as a specialized player in niche therapeutic areas. The current investor narrative is dominated by the company's transition from a pure R&D entity to one with commercial revenue streams, with intense focus on the growth trajectory of its marketed products and the progress of its clinical-stage assets like brensocatib, which represent significant potential catalysts but also require substantial ongoing investment.…
INSM
Insmed, Inc.
$117.99
Related headlines
Investment Opinion: Should I buy INSM Today?
Rating: Hold. The core thesis is that while Insmed's commercial growth is impressive, the extreme valuation and profound cash burn create an asymmetric risk/reward profile that currently favors caution, awaiting either a more attractive entry point or de-risking pipeline catalysts.
Supporting this Hold rating are several key data points: 1) The stock trades at a stratospheric PS ratio of 61.31, implying near-perfect future execution. 2) Despite 152.6% YoY revenue growth, operating losses remain massive at -94.6% margin. 3) Free cash flow is deeply negative at -$997.6 million TTM. 4) The stock's severe negative momentum (-29.72% over 6 months) suggests the market is already repricing these risks, but the valuation remains elevated relative to the financial reality.
The two biggest risks invalidating a Hold are a clinical failure (downgrade to Sell) or a dramatic acceleration in profitability (upgrade to Buy). This Hold would upgrade to a Buy if the PS ratio compresses meaningfully below its historical low range (towards 40x) without a fundamental deterioration, or if the company provides a credible path to significantly reduced cash burn. It would downgrade to a Sell if revenue growth decelerates sharply below 50% or a key pipeline asset fails. Relative to its financial fundamentals and the binary nature of its pipeline, the stock is overvalued.
Sign up to view all
INSM 12-Month Price Forecast
The outlook is bifurcated and highly dependent on binary clinical outcomes and the pace of cash burn reduction. The base case of volatile, range-bound trading is most likely, given the offsetting forces of strong commercial traction and severe financial losses. The neutral stance reflects this stalemate. An upgrade to bullish would require evidence that operating losses are peaking and a clear path to cash flow breakeven emerges. A downgrade to bearish would be triggered by a clinical failure or a material slowdown in the revenue growth that justifies its valuation.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Insmed, Inc.'s 12-month outlook, with a consensus price target around $153.39 and implied upside of +30.0% versus the current price.
Average Target
$153.39
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$94 - $153
Analyst target range
Insufficient detailed analyst coverage data (e.g., consensus price target, buy/hold/sell breakdown) is available in the provided dataset to perform a standard consensus and sentiment analysis. The data shows eight analysts providing estimates, with an average revenue estimate of approximately $6.52 billion, but lacks the crucial average price target and rating distribution. The implications of limited explicit target data are that while the company is covered, the investment thesis is highly complex and binary, often leading to a wide dispersion of views on valuation; the recent institutional ratings from firms like Morgan Stanley (upgraded to Overweight), Mizuho, and Wells Fargo (maintaining Overweight/Buy ratings) in March 2026 suggest a maintained bullish institutional stance despite the stock's sharp decline, indicating analysts may be looking through near-term volatility to long-term pipeline value.
Bulls vs Bears: INSM Investment Factors
The investment debate for Insmed is a classic high-risk, high-reward biotech story, with the bull case anchored in explosive commercial growth and a valuable pipeline, and the bear case focused on unsustainable cash burn and a precarious valuation. Currently, the bearish evidence appears stronger due to the stock's severe technical breakdown and the stark reality of its financial losses, which the current sky-high sales multiples do not justify. The single most important tension is the race between revenue scaling to eventually cover massive operating expenses versus the risk of a financing or clinical setback that could force dilution or a collapse in the growth-premium valuation. The resolution of this cash burn timeline will determine the investment outcome.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue of $263.8 million grew 152.6% year-over-year, demonstrating powerful commercial execution for its launched products Arikayce and Brinsupri. This sequential growth from $92.8 million in Q1 2025 suggests strong market adoption and a successful transition from R&D to a commercial-stage company.
- High Gross Margin Profile: The company maintains a robust gross margin of 82.5% (Q4 2025), which is characteristic of successful biopharmaceuticals and provides a strong foundation for future profitability. This high margin indicates pricing power and efficient manufacturing for its niche respiratory therapies.
- Despite the stock's sharp decline, major institutions like Morgan Stanley and Wells Fargo maintained Overweight/Buy ratings in March 2026, signaling professional confidence in the long-term pipeline value. This suggests analysts are looking through near-term cash burn to the potential of clinical-stage assets like brensocatib.
- Significant Pipeline Optionality: The company's pipeline spans three therapeutic areas (Respiratory, Immunology, Neuro/Rare) with multiple clinical-stage programs, offering several potential catalysts. This diversification reduces binary risk compared to single-asset biotechs and provides multiple shots on goal for value creation.
Bearish
- Massive Cash Burn & Losses: The company is deeply unprofitable, with a Q4 2025 net loss of $328.5 million and an operating margin of -94.6%. Trailing twelve-month free cash flow is -$997.6 million, indicating a heavy and ongoing reliance on external financing to fund operations and R&D.
- Extremely High Valuation Multiples: Insmed trades at a trailing Price-to-Sales (PS) ratio of 61.31 and EV/Sales of 47.34, multiples that are exceptionally high and imply near-perfect execution of exponential future growth. This leaves the stock vulnerable to severe multiple compression if revenue growth decelerates or clinical trials disappoint.
- Severe Negative Momentum: The stock is in a pronounced downtrend, down 29.72% over six months and 24.76% year-to-date, with recent momentum accelerating the decline (-19.17% over one month). This technical breakdown suggests persistent selling pressure and a loss of investor confidence, diverging sharply from the still-positive 1-year return of 83.45%.
- Leveraged Balance Sheet: A debt-to-equity ratio of 1.04 indicates a leveraged capital structure, which increases financial risk given the company's substantial and ongoing cash burn. While the current ratio of 3.83 shows short-term liquidity, the combination of high debt and negative cash flow pressures financial flexibility.
INSM Technical Analysis
The prevailing price trend for Insmed is a pronounced downtrend from recent highs, with the stock down 29.72% over the past six months and 24.76% year-to-date as of the analysis date. Currently trading at $133.26, the stock sits at approximately 63% of its 52-week range (between $63.81 and $212.75), indicating it has retreated significantly from its highs and is now in the lower half of its annual range, suggesting a potential value zone but also reflecting persistent negative momentum. Recent momentum is decisively negative and accelerating the longer-term decline, with the stock down 19.17% over the past month and 15.05% over the past three months, a stark divergence from its still-positive 1-year return of 83.45%, signaling a sharp reversal from the prior bullish trend likely driven by fundamental concerns or sector-wide pressure. Key technical support is clearly defined at the 52-week low of $63.81, while resistance lies at the 52-week high of $212.75; a breakdown below the recent trading range could test the multi-year low, whereas a sustained move above the $160-$170 area would be needed to suggest a reversal, with the stock's beta of 1.101 indicating it is roughly 10% more volatile than the broader market, which is relevant for risk assessment given its current high volatility.
Beta
0.89
0.89x market volatility
Max Drawdown
-52.1%
Largest decline past year
52-Week Range
$65-$213
Price range past year
Annual Return
+79.6%
Cumulative gain past year
| Period | INSM Return | S&P 500 |
|---|---|---|
| 1m | -21.9% | +8.2% |
| 3m | -19.3% | +9.0% |
| 6m | -38.9% | +10.5% |
| 1y | +79.6% | +26.5% |
| ytd | -33.4% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INSM Fundamental Analysis
Insmed's revenue trajectory shows significant growth, with Q4 2025 revenue of $263.8 million representing a robust 152.6% year-over-year increase, building sequentially from $92.8 million in Q1 2025, indicating strong commercial execution for its launched products. Despite this top-line expansion, the company remains deeply unprofitable, reporting a Q4 2025 net loss of $328.5 million and an operating margin of -94.6%, though the gross margin of 82.5% is healthy for a biotech, the substantial operating losses are driven by heavy R&D ($254.9 million in Q4) and SG&A expenses as it invests in commercialization and pipeline development. The balance sheet and cash flow position reveal a company burning significant cash to fund growth, with trailing twelve-month free cash flow of -$997.6 million, a debt-to-equity ratio of 1.04 indicating a leveraged capital structure, and a current ratio of 3.83 showing ample short-term liquidity, but the consistent and large negative operating and free cash flows underscore a reliance on external financing to sustain operations and advance its clinical pipeline.
Quarterly Revenue
$263843000.0B
2025-12
Revenue YoY Growth
+1.52%
YoY Comparison
Gross Margin
+0.82%
Latest Quarter
Free Cash Flow
$-997575000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INSM Overvalued?
Given the company's consistently negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. Insmed trades at a trailing PS ratio of 61.31 and an Enterprise Value-to-Sales (EV/Sales) of 47.34, with no meaningful forward PS available for comparison, indicating the market is valuing its current revenue stream at an extremely high multiple based on future growth expectations. A direct peer comparison for the biotechnology industry is not provided in the dataset, but such elevated sales multiples typically signify the market is pricing in exponential future revenue growth and pipeline success, not current profitability. Historically, the stock's own PS ratio has fluctuated wildly, from a low near 35.65 in early 2023 to a high of 214.24 in Q3 2025; the current PS of 61.31 is below the peak but still significantly above the lower end of its historical range, suggesting expectations remain elevated but have moderated from recent optimism.
PE
-29.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -28x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-32.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on the company's unsustainable cash consumption. With a Q4 2025 net loss of $328.5 million and TTM free cash flow of -$997.6 million, Insmed is burning cash at an alarming rate to fund both commercialization and a broad clinical pipeline. The debt-to-equity ratio of 1.04 adds financial leverage risk to this cash burn profile. Revenue, while growing rapidly at 152.6% YoY, is still insufficient to cover operating expenses, creating a dependency on continued capital market access for survival.
Market & Competitive Risks are dominated by extreme valuation compression risk. Trading at a PS ratio of 61.31, the stock is priced for flawless execution of its pipeline and commercial plans. Any disappointment—slower revenue growth, a clinical trial failure, or increased competition in its niche respiratory markets—could trigger a severe derating. The stock's beta of 1.101 indicates it is more volatile than the market, amplifying downside moves during sector-wide selloffs or periods of rising risk aversion for pre-profitability biotechs.
Worst-Case Scenario involves a combination of a clinical pipeline setback (e.g., brensocatib missing endpoints), concurrent slowing of commercial revenue growth, and a tightening financing environment. This could lead to a liquidity crisis, forcing highly dilutive equity financing or restructuring. The realistic downside could see the stock re-testing its 52-week low of $63.81, representing a potential loss of approximately -52% from the current price of $133.26. A drawdown of this magnitude is plausible given the stock's historical PS ratio low near 35.65 and the high binary risk inherent in its development-stage pipeline.
FAQ
The key risks are, in order of severity: 1) Financial Sustainability Risk: Burning $997.6M annually in cash with a leveraged balance sheet (D/E of 1.04) creates a constant need for financing. 2) Valuation Risk: The PS ratio of 61.31 leaves enormous room for downside if growth slows. 3) Clinical/Regulatory Risk: The value of pipeline assets like brensocatib is binary and unproven. 4) Execution Risk: Successfully scaling commercial operations while managing R&D spend is a complex operational challenge. Any one of these could materially impair the stock price.
The 12-month forecast is highly uncertain, with three distinct scenarios. The base case (50% probability) sees the stock trading between $135 and $165, as strong revenue growth battles high cash burn. The bull case (25% probability) could drive the stock to $190-$212 on positive clinical data. The bear case (25% probability) could see a collapse to $64-$100 on a clinical failure or financing crisis. The base case is most likely, implying a volatile but potentially range-bound year ahead.
Based on conventional metrics, INSM appears significantly overvalued. It trades at a Price-to-Sales ratio of 61.31, an extreme multiple that prices in years of flawless exponential growth and pipeline success. With no profits and deeply negative cash flows, this valuation is not supported by current fundamentals. The market is paying a large premium for future optionality, implying that any stumble in growth or clinical development could lead to severe multiple compression.
INSM is a speculative buy only for investors with a high risk tolerance and a long time horizon who can stomach significant volatility. The 152.6% YoY revenue growth is compelling, but it is offset by a massive $997.6M annual cash burn and a sky-high PS ratio of 61.31. The stock could be a good buy for those who believe in the pipeline's success and can accept the risk of a ~52% drawdown to its 52-week low. It is not suitable for conservative or income-seeking investors.
INSM is unsuitable for short-term trading due to its high beta (1.101) and binary event risk around clinical data. It is a long-term, speculative investment for investors willing to hold for 3-5 years to see the pipeline mature and the path to profitability clarify. The company pays no dividend and has no earnings visibility, eliminating it as an income or short-term play. A minimum holding period of 18-24 months is suggested to navigate through upcoming clinical catalysts and several financing cycles.